Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) was upgraded by analysts at Mizuho to a “strong-buy” rating in a research note issued on Monday, Zacks reports.
A number of other equities analysts also recently weighed in on EIKN. Wedbush dropped their target price on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating for the company in a research note on Friday, August 14th. Weiss Ratings raised shares of Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.00.
View Our Latest Report on EIKN
Eikon Therapeutics Stock Down 1.4%
Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.02). As a group, sell-side analysts anticipate that Eikon Therapeutics will post -7.24 EPS for the current year.
Insiders Place Their Bets
In other Eikon Therapeutics news, major shareholder Group Iv Gp Lp Column acquired 89,200 shares of Eikon Therapeutics stock in a transaction on Thursday, September 3rd. The shares were purchased at an average cost of $11.56 per share, with a total value of $1,031,152.00. Following the completion of the purchase, the insider owned 89,200 shares in the company, valued at $1,031,152. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Institutional Trading of Eikon Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Eikon Therapeutics during the 2nd quarter valued at $28,000. California State Teachers Retirement System bought a new position in shares of Eikon Therapeutics in the 2nd quarter worth $51,000. The Manufacturers Life Insurance Company boosted its position in shares of Eikon Therapeutics by 23.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock worth $461,000 after purchasing an additional 6,734 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Eikon Therapeutics during the second quarter worth $142,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Eikon Therapeutics during the second quarter worth $170,000.
About Eikon Therapeutics
We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.
Read More
- Five stocks we like better than Eikon Therapeutics
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Eikon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eikon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
